EOLS

Evolus, Inc.

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Evolus, Inc. (EOLS) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Growth (C).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B-
Factor Score 3.1 / 5.0
Growth
C
Factor Score 2.4 / 5.0
Profitability
B-
Factor Score 3.1 / 5.0
Momentum
B-
Factor Score 3.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 22.3
EV / EBITDA -69.4
Rev Growth YoY 13.0%
Gross Margin 66.1%
Price Return 3M -16.1%
Price Return 12M 3.8%
Catalyst Signal 0.00
Market Cap $450.7M
TTM Revenue $325.5M
Price / Sales 1.4
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (3.1) C (2.4) B- (3.1) B- (3.1) C+ (2.6) C+ (2.8)
2026-11-04 B- (3.0) C+ (2.6) B- (3.1) B+ (3.6) C+ (2.7) B- (3.0)
2026-10-28 B- (3.0) C+ (2.5) B- (3.1) B+ (3.8) C+ (2.7) B- (3.0)
2026-10-21 B- (3.0) C+ (2.5) B- (3.1) A- (4.0) C+ (2.6) B- (3.0)
2026-10-14 B- (3.0) C+ (2.6) B- (3.1) A- (4.1) C+ (2.6) B- (3.1)
Page 1 of 7